PSNL stock forecast, quote, news & analysis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies... Show more
Why Personalis (PSNL) Stock Is Up +14% in the Last 30 Days
Key Takeaways
- Personalis shares have risen roughly 14% over the trailing 30 days, climbing from about $14.21 to near $16.25 per share.
- The move is anchored to Tempus AI (TEM)'s agreement to acquire Personalis for $16.25 per share, announced on July 20, 2026.
- Mid-August gains were amplified by positive cancer-vaccine trial data from Moderna (MRNA), which briefly pushed PSNL toward the top of its 52-week range.
- A subsequent Craig-Hallum downgrade to Hold tempered the rally, with analysts citing a low probability of a competing higher bid.
- Over the last quarter, the stock has climbed roughly 72%, reflecting takeover speculation that preceded the announced deal.
Personalis (PSNL) Company Overview and Market Position
Personalis is a cancer genomics company headquartered in Fremont, California, focused on detecting molecular residual disease (MRD) and supporting precision oncology. Its flagship product, NeXT Personal, is a tumor-informed, whole-genome-sequencing liquid biopsy that tracks circulating tumor DNA to detect early signs of cancer recurrence, while NeXT Dx and the ImmunoID NeXT platform serve clinical profiling and biopharmaceutical research customers. The company sells into three segments: clinical oncologists ordering MRD surveillance, biopharmaceutical firms running oncology trials, and large-scale population sequencing programs. Investors follow the stock for its high-sensitivity MRD technology, growing Medicare reimbursement coverage, and its role in the broader personalized-medicine market.
Personalis (PSNL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Personalis shares have advanced approximately 14%, moving from a closing level near $14.21 in mid-August to roughly $16.25. The period was volatile: the stock spiked toward $18.38 around mid-August before pulling back following an analyst downgrade, then stabilized near the $16.25 acquisition price.
The quarterly picture is stronger. About three months earlier, shares traded near $9.42, meaning the stock has risen roughly 72% over the last quarter. This multi-month advance reflects pre-deal takeover speculation and the subsequent announcement of the Tempus AI acquisition, with the share price now tracking the agreed transaction value.
What Drove PSNL Stock Price in the Last 30 Days
The dominant force behind PSNL over the last 30 days has been merger-related news flow. On July 20, 2026, Tempus AI announced a definitive agreement to acquire Personalis for $16.25 per share, representing an enterprise value of about $1.5 billion net of Tempus's existing ownership stake. The all-stock deal, with an option for up to 50% cash, is expected to close in late 2026 or early 2027 pending shareholder and regulatory approvals.
During August, sentiment was lifted by Moderna (MRNA)'s announcement of positive late-stage results for an mRNA cancer vaccine being developed with Merck (MRK), which briefly drove PSNL higher on renewed enthusiasm for personalized cancer-vaccine supply chains. The rally was later cooled when Craig-Hallum downgraded Personalis from Buy to Hold with a $16.25 price target, arguing that a competing higher bid was unlikely given Tempus's role as Personalis's commercial partner for NeXT Personal. Needham had similarly moved to Hold following the original deal announcement.
What Drove PSNL Stock Performance Over the Last Quarter
The broader quarterly narrative centers on consolidation in the MRD and precision-oncology space. Before the Tempus agreement was announced, reports indicated that Personalis had been exploring a potential sale and had attracted interest from Merck and other suitors, fueling a rally from single-digit levels. The formal Tempus AI acquisition then crystallized the company's path, capping the share price near the transaction value. Underpinning this activity, Personalis reported preliminary second-quarter revenue of approximately $22.4 million and delivered 10,384 clinical tests, a 33% quarter-over-quarter increase, while continuing to expand Medicare coverage across breast and non-small-cell lung cancer surveillance indications.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing automated trading strategies. Tickeron offers hundreds of AI trading bots that operate across thousands of tickers, but only the most relevant and consistently strong performers appear in this featured section. The bots vary widely in strategy, holding timeframe, and performance metrics, allowing users to browse approaches ranging from short-term momentum to longer-horizon trend following. For traders seeking a data-driven complement to their own research, exploring the trending robots can provide a useful starting point for identifying active strategies.
PSNL Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term factor for PSNL is the completion of the Tempus AI acquisition. Key milestones include the Personalis stockholder vote, Hart-Scott-Rodino antitrust clearance, and other customary closing conditions, with the transaction expected to close in late 2026 or early 2027. Investors should also monitor Tempus's own share price, since the consideration carries a floating exchange ratio subject to a maximum of 0.3356 Tempus shares per Personalis share. On the fundamentals side, continued growth in NeXT Personal test volume and reimbursement expansion, as well as Personalis's quarterly financial results, remain relevant to the company's standalone trajectory while the deal is pending.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PSNL's Stochastic Oscillator stays in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where PSNL advanced for three days, in 211 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 128 of 148 cases where PSNL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for PSNL moved out of overbought territory on August 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 23 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Momentum Indicator moved below the 0 level on September 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PSNL as a result. In 77 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for PSNL turned negative on September 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PSNL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
PSNL broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PSNL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.364) is normal, around the industry mean (60.137). P/E Ratio (0.000) is within average values for comparable stocks, (156.768). PSNL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.504). PSNL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (22.727) is also within normal values, averaging (9.865).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PSNL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.
Industry MedicalSpecialties